{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T03:20:55Z","timestamp":1787887255937,"version":"build-2784847793"},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T00:00:00Z","timestamp":1726617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Department of Gastroenterology & Hepatology of the Amsterdam University Medical Center, Amsterdam, the Netherlands"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Patients with liver cirrhosis are prone to develop severe bacterial infections. Pharmacokinetics (PK) of antibiotics in cirrhosis are potentially affected by impaired biotransformation phases 0\u20133 and consequences of portal hypertension such as portovenous shunting, ascites formation and\/or acute kidney injury (AKI). We aimed to elucidate to what extent PK of selected antibiotics and, therefore, dosage recommendations are affected in adults with cirrhosis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We performed a systematic search in PubMed, Embase, Cochrane and CINAHL on effects of cirrhosis on PK profiles of ceftriaxone, fosfomycin, gentamicin, meropenem, nitrofurantoin, piperacillin\/tazobactam and vancomycin in adults. Antibiotics were selected based on the lack of specific dosing recommendations for adults with cirrhosis. We included studies reporting on \u22651 of the following PK parameters: AUC, half-life (t\u00bd), CL, volume of distribution (Vd), peak (Cmax) or trough concentrations (Cmin).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We identified 15 studies (ceftriaxone, n\u200a=\u200a5; gentamicin, n\u200a=\u200a3; meropenem n\u200a=\u200a5; vancomycin, n\u200a=\u200a2), including 379 patients with cirrhosis, of which two were of high quality. No eligible studies were identified for fosfomycin, nitrofurantoin or piperacillin\/tazobactam. Ceftriaxone unbound concentration increased in cirrhosis, but was mitigated by increased renal CL. Gentamicin levels in ascitic fluid were comparable to those in plasma. Meropenem PK parameters were not altered in cirrhosis without AKI, but in the presence of AKI a decrease in CL was observed. In contrast, vancomycin CL decreased in advanced cirrhosis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Available data in studies of mostly moderate quality suggest that PK of ceftriaxone, meropenem and vancomycin are altered in cirrhosis. More advanced PK studies are needed to provide specific dosing recommendations.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkae310","type":"journal-article","created":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T04:15:09Z","timestamp":1726632909000},"page":"2750-2761","source":"Crossref","is-referenced-by-count":8,"title":["Pharmacokinetics of ceftriaxone, gentamicin, meropenem and vancomycin in liver cirrhosis: a systematic review"],"prefix":"10.1093","volume":"79","author":[{"given":"M H","family":"Comce","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Amsterdam UMC, University of Amsterdam, Amsterdam Gastroenterology Endocrinology Metabolism , Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R A","family":"Weersink","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Deventer Hospital , Deventer ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U","family":"Beuers","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Amsterdam UMC, University of Amsterdam, Amsterdam Gastroenterology Endocrinology Metabolism , Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2506-8795","authenticated-orcid":false,"given":"R M","family":"van Hest","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Clinical Pharmacology, Amsterdam UMC, University of Amsterdam, Amsterdam Infection & Immunity, Amsterdam Gastroenterology Endocrinology Metabolism , Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M A","family":"Lantinga","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Amsterdam UMC, University of Amsterdam, Amsterdam Gastroenterology Endocrinology Metabolism , Amsterdam ,","place":["The Netherlands"]},{"name":"European Reference Network on Hepatological Diseases (ERN RARE-LIVER) , Hamburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,9,18]]},"reference":[{"key":"2024110323521747200_dkae310-B1","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1136\/jcp.31.5.395","article-title":"The morphology of cirrhosis. Recommendations on definition, nomenclature, and classification by a working group sponsored by the World Health Organization","volume":"31","author":"Anthony","year":"1978","journal-title":"J Clin Pathol"},{"key":"2024110323521747200_dkae310-B2","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2021.06.018","article-title":"Towards a new definition of decompensated cirrhosis","volume":"76","author":"D\u2019Amico","year":"2022","journal-title":"J Hepatol"},{"key":"2024110323521747200_dkae310-B3","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S1726-4901(09)70072-3","article-title":"Bacterial infections in patients with cirrhosis","volume":"68","author":"Yang","year":"2005","journal-title":"J Chin Med Assoc"},{"key":"2024110323521747200_dkae310-B4","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1056\/NEJMra1914900","article-title":"Acute-on-chronic liver failure","volume":"382","author":"Arroyo","year":"2020","journal-title":"N Engl J Med"},{"key":"2024110323521747200_dkae310-B5","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1053\/j.gastro.2010.06.019","article-title":"Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis","volume":"139","author":"Arvaniti","year":"2010","journal-title":"Gastroenterology"},{"key":"2024110323521747200_dkae310-B6","first-page":"233","article-title":"Morbidity and mortality of infections in the cirrhotic patients: a US population-based study","volume":"12","author":"Saleem","year":"2019","journal-title":"Gastroenterol Hepatol Bed Bench"},{"key":"2024110323521747200_dkae310-B7","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s00228-008-0553-z","article-title":"Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction","volume":"64","author":"Verbeeck","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"2024110323521747200_dkae310-B8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3390\/antibiotics11010031","article-title":"Antibiotics and liver cirrhosis: what the physicians need to know","volume":"11","author":"Zoratti","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"2024110323521747200_dkae310-B9","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1159\/000090185","article-title":"Hypoalbuminemia in renal failure: pathogenesis and therapeutic considerations","volume":"28","author":"Haller","year":"2005","journal-title":"Kidney Blood Press Res"},{"issue":"Suppl 3","key":"2024110323521747200_dkae310-B10","doi-asserted-by":"publisher","first-page":"S193","DOI":"10.1007\/s11739-012-0802-0","article-title":"Hypoalbuminemia","volume":"7","author":"Gatta","year":"2012","journal-title":"Intern Emerg Med"},{"key":"2024110323521747200_dkae310-B11","doi-asserted-by":"publisher","first-page":"5552","DOI":"10.3748\/wjg.v13.i42.5552","article-title":"Acute renal dysfunction in liver diseases","volume":"13","author":"Betrosian","year":"2007","journal-title":"World J Gastroenterol"},{"key":"2024110323521747200_dkae310-B12","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1056\/NEJMra2215289","article-title":"Acute kidney injury in patients with cirrhosis","volume":"388","author":"Nadim","year":"2023","journal-title":"N Engl J Med"},{"key":"2024110323521747200_dkae310-B13","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.jhep.2018.03.024","article-title":"EASL clinical practice guidelines for the management of patients with decompensated cirrhosis","volume":"69","author":"Angeli","year":"2018","journal-title":"J Hepatol"},{"key":"2024110323521747200_dkae310-B14","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.2146\/ajhp140031","article-title":"Antibiotic dosing in cirrhosis","volume":"71","author":"Halilovic","year":"2014","journal-title":"Am J Health Syst Pharm"},{"key":"2024110323521747200_dkae310-B15","author":"KNMP"},{"key":"2024110323521747200_dkae310-B16","doi-asserted-by":"publisher","first-page":"e012991","DOI":"10.1136\/bmjopen-2016-012991","article-title":"Evaluating the safety and dosing of drugs in patients with liver cirrhosis by literature review and expert opinion","volume":"6","author":"Weersink","year":"2016","journal-title":"BMJ Open"},{"key":"2024110323521747200_dkae310-B17","author":"Drugs in liver cirrhosis"},{"key":"2024110323521747200_dkae310-B18","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"2024110323521747200_dkae310-B19","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.3390\/ph15121501","article-title":"Assessing clinical potential of old antibiotics against severe infections by multi-drug-resistant gram-negative bacteria using in silico modelling","volume":"15","author":"Paranos","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"2024110323521747200_dkae310-B20","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s40262-015-0236-8","article-title":"Reporting guidelines for clinical pharmacokinetic studies: the ClinPK statement","volume":"54","author":"Kanji","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"2024110323521747200_dkae310-B21","doi-asserted-by":"publisher","first-page":"1056148","DOI":"10.3389\/fphar.2022.1056148","article-title":"Systematic review of efficacy, safety and pharmacokinetics of intravenous and intraventricular vancomycin for central nervous system infections","volume":"13","author":"Liu","year":"2022","journal-title":"Front Pharmacol"},{"key":"2024110323521747200_dkae310-B22","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s13318-022-00762-z","article-title":"Systematic review and pharmacokinetic meta-analysis of doxorubicin exposure in transcatheter arterial chemoembolization and doxorubicin-eluted beads chemoembolization for treatment of unresectable hepatocellular carcinoma","volume":"47","author":"Zarisfi","year":"2022","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"2024110323521747200_dkae310-B23","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s40262-022-01116-3","article-title":"Pharmacokinetics of clavulanic acid in the pediatric population: a systematic literature review","volume":"61","author":"Keij","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"2024110323521747200_dkae310-B24","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2024110323521747200_dkae310-B25","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1128\/AAC.37.8.1587","article-title":"Randomized trial comparing ceftriaxone with cefonicid for treatment of spontaneous bacterial peritonitis in cirrhotic patients","volume":"37","author":"G\u00f3mez-Jim\u00e9nez","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"2024110323521747200_dkae310-B26","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/BF00637745","article-title":"The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites","volume":"36","author":"Hary","year":"1989","journal-title":"Eur J Clin Pharmacol"},{"key":"2024110323521747200_dkae310-B27","first-page":"59","article-title":"Variability of ceftriaxone pharmacokinetics in hospitalized patients with severe infections","volume":"77","author":"Joos","year":"1984","journal-title":"Am J Med"},{"key":"2024110323521747200_dkae310-B28","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/bcp.12636","article-title":"Protein binding characteristics and pharmacokinetics of ceftriaxone in intensive care unit patients","volume":"80","author":"Schleibinger","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"2024110323521747200_dkae310-B29","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/clpt.1984.210","article-title":"Single-dose ceftriaxone kinetics in liver insufficiency","volume":"36","author":"Stoeckel","year":"1984","journal-title":"Clin Pharmacol Ther"},{"key":"2024110323521747200_dkae310-B30","first-page":"634","article-title":"Pharmacology of gentamicin in patients with spontaneous bacterial peritonitis","volume":"20","author":"Berger","year":"1984","journal-title":"Isr J Med Sci"},{"key":"2024110323521747200_dkae310-B31","first-page":"191","article-title":"Concentrations of gentamicin in ascitic fluid after intravenous infusion","volume":"26","author":"Fevery","year":"1983","journal-title":"Neth J Med"},{"key":"2024110323521747200_dkae310-B32","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1128\/AAC.19.2.312","article-title":"Peritoneal fluid concentrations of gentamicin in patients with spontaneous bacterial peritonitis","volume":"19","author":"Richey","year":"1981","journal-title":"Antimicrob Agents Chemother"},{"key":"2024110323521747200_dkae310-B33","doi-asserted-by":"publisher","first-page":"3619","DOI":"10.1093\/jac\/dkaa362","article-title":"Meropenem population pharmacokinetics in patients with decompensated cirrhosis and severe infections","volume":"75","author":"Bastida","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2024110323521747200_dkae310-B34","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13613-020-00666-8","article-title":"Acute-on-chronic liver failure alters meropenem pharmacokinetics in critically ill patients with continuous hemodialysis: an observational study","volume":"10","author":"Grensemann","year":"2020","journal-title":"Ann Intensive Care"},{"key":"2024110323521747200_dkae310-B35","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.jhep.2021.07.015","article-title":"Plasma and ascites pharmacokinetics of meropenem in patients with decompensated cirrhosis and spontaneous bacterial peritonitis","volume":"76","author":"Griemsmann","year":"2022","journal-title":"J Hepatol"},{"key":"2024110323521747200_dkae310-B36","doi-asserted-by":"publisher","first-page":"A410","DOI":"10.1186\/2197-425X-3-S1-A401","article-title":"\u03b2-Lactams serum concentrations in critically ill cirrhotic patients: a matched-control study","volume":"3","author":"Lheureux","year":"2015","journal-title":"ICMx"},{"issue":"Suppl 2","key":"2024110323521747200_dkae310-B37","doi-asserted-by":"publisher","first-page":"S184","DOI":"10.1093\/clinids\/24.Supplement_2.S184","article-title":"Pharmacokinetics of meropenem in patients with liver disease","volume":"24","author":"Thyrum","year":"1997","journal-title":"Clin Infect Dis"},{"key":"2024110323521747200_dkae310-B38","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12941-020-00354-2","article-title":"The risk of vancomycin toxicity in patients with liver impairment","volume":"19","author":"Brunetti","year":"2020","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"2024110323521747200_dkae310-B39","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s101560050018","article-title":"Study of the pharmacokinetics of vancomycin in patients with impaired liver function","volume":"5","author":"Harada","year":"1999","journal-title":"J Infect Chemother"},{"key":"2024110323521747200_dkae310-B40","author":"DAILYMED"},{"key":"2024110323521747200_dkae310-B41","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.3109\/00498258709167406","article-title":"Plasma protein binding of ceftriaxone","volume":"17","author":"Popick","year":"1987","journal-title":"Xenobiotica"},{"key":"2024110323521747200_dkae310-B42","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1002\/jps.2600781005","article-title":"Factors affecting ceftriaxone plasma protein binding during open heart surgery","volume":"78","author":"Jungbluth","year":"1989","journal-title":"J Pharm Sci"},{"key":"2024110323521747200_dkae310-B43","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/clpt.1981.90","article-title":"Effects of concentration-dependent plasma protein binding on ceftriaxone kinetics","volume":"29","author":"Stoeckel","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"2024110323521747200_dkae310-B44","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/jac\/16.2.267","article-title":"Pharmacokinetics of ceftazidime and ceftriaxone and their penetration into the ascitic fluid","volume":"16","author":"Benoni","year":"1985","journal-title":"J Antimicrobial Chemother"},{"key":"2024110323521747200_dkae310-B45","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.dld.2013.07.015","article-title":"Management of infections in cirrhotic patients: report of a consensus conference","volume":"46","author":"Fagiuoli","year":"2014","journal-title":"Dig Liver Dis"},{"key":"2024110323521747200_dkae310-B46","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/0016-5085(82)90129-9","article-title":"Aminoglycoside nephrotoxicity in cirrhosis. Value of urinary \u03b22-microglobulin to discriminate functional renal failure from acute tubular damage","volume":"82","author":"Cabrera","year":"1982","journal-title":"Gastroenterology"},{"issue":"Suppl 2","key":"2024110323521747200_dkae310-B47","doi-asserted-by":"publisher","first-page":"S249","DOI":"10.1093\/clinids\/24.Supplement_2.S249","article-title":"Pharmacokinetics of meropenem in animals, healthy volunteers, and patients","volume":"24","author":"Moon","year":"1997","journal-title":"Clin Infect Dis"},{"key":"2024110323521747200_dkae310-B48","doi-asserted-by":"publisher","first-page":"275","DOI":"10.2165\/00003088-199528040-00002","article-title":"Meropenem clinical pharmacokinetics","volume":"28","author":"Mouton","year":"1995","journal-title":"Clin Pharmacokinet"},{"key":"2024110323521747200_dkae310-B49","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2165\/00003088-200039040-00003","article-title":"Pharmacokinetics of meropenem in patients with renal failure and patients receiving renal replacement therapy","volume":"39","author":"Thalhammer","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"2024110323521747200_dkae310-B50","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/j.1365-2885.2004.00602.x","article-title":"Volumes of distribution","volume":"27","author":"Toutain","year":"2004","journal-title":"J Vet Pharmacol Ther"},{"key":"2024110323521747200_dkae310-B51","doi-asserted-by":"publisher","first-page":"257","DOI":"10.2165\/00003088-198611040-00001","article-title":"Clinical pharmacokinetics of vancomycin","volume":"11","author":"Matzke","year":"1986","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl D","key":"2024110323521747200_dkae310-B52","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1093\/jac\/14.suppl_D.43","article-title":"Pharmacokinetics of vancomycin","volume":"14","author":"Moellering","year":"1984","journal-title":"J Antimicrob Chemother"},{"key":"2024110323521747200_dkae310-B53","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jhep.2018.12.030","article-title":"Estimation of renal function in patients with liver cirrhosis: impact of muscle mass and sex","volume":"70","author":"Yoo","year":"2019","journal-title":"J Hepatol"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/11\/2750\/60271957\/dkae310.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/11\/2750\/60271957\/dkae310.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,3]],"date-time":"2024-11-03T23:52:25Z","timestamp":1730677945000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/79\/11\/2750\/7759750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,18]]},"references-count":53,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,9,18]]},"published-print":{"date-parts":[[2024,11,4]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkae310","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2024,9,18]]}}}